Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,038 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.
Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G. Tornatore L, et al. Among authors: benjamin r. Br J Haematol. 2019 May;185(3):588-592. doi: 10.1111/bjh.15569. Epub 2018 Sep 26. Br J Haematol. 2019. PMID: 30255568 Free article. No abstract available.
Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
Richardson SE, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, Fielding AK, Goldstone A, Kottaridis P, Morris E, Benjamin R, Peggs KS, Thomson KJ, Vandenberghe E, Mackinnon S, Chakraverty R. Richardson SE, et al. Among authors: benjamin r. Br J Haematol. 2013 Mar;160(5):640-8. doi: 10.1111/bjh.12197. Epub 2013 Jan 7. Br J Haematol. 2013. PMID: 23293871 Free article.
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Maciocia N, Melville A, Cheesman S, Sharpley F, Ramasamy K, Streetly M, Jenner M, Benjamin R, Schey S, Maciocia P, Popat R, D'sa S, Rismani A, Cerner A, Yong K, Rabin N. Maciocia N, et al. Among authors: benjamin r. Br J Haematol. 2017 Mar;176(6):908-917. doi: 10.1111/bjh.14547. Epub 2017 Feb 17. Br J Haematol. 2017. PMID: 28211054 Free article.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Dimopoulos MA, et al. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. Lancet. 2019. PMID: 30545780 Clinical Trial.
The combination of an inclusive novel agent treatment strategy, pre-emptive therapy dose reduction, and prolonged therapy results in good outcomes in elderly myeloma patients.
Ediriwickrama N, Oyebamiji T, Munisamy S, Garland P, Cuthill K, Benjamin R, Ceesay MM, Bowcock S. Ediriwickrama N, et al. Among authors: benjamin r. Br J Haematol. 2019 Aug;186(3):e11-e13. doi: 10.1111/bjh.15848. Epub 2019 Mar 12. Br J Haematol. 2019. PMID: 30864155 Free article. No abstract available.
Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3.
Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G. Tornatore L, et al. Among authors: benjamin r. Toxicol Rep. 2019 Apr 19;6:369-379. doi: 10.1016/j.toxrep.2019.04.006. eCollection 2019. Toxicol Rep. 2019. PMID: 31080744 Free PMC article.
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Camilleri M, Cuadrado M, Phillips E, Wilson W, Jenner R, Pang G, Kamora S, Streetly M, Popat R, Bygrave C, Owen R, Cavenagh J, Chapman M, Sive J, Eccersley L, Sheaff M, Benjamin R, Ramasamy K, Cook G, Virchis A, Chavda SJ, Clifton-Hadley L, Scully MA, Yong K. Camilleri M, et al. Among authors: benjamin r. Br J Haematol. 2021 May;193(4):750-760. doi: 10.1111/bjh.17377. Epub 2021 Mar 1. Br J Haematol. 2021. PMID: 33650100 Clinical Trial.
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Mateos MV, Gavriatopoulou M, Facon T, Auner HW, Leleu X, Hájek R, Dimopoulos MA, Delimpasi S, Simonova M, Špička I, Pour L, Kriachok I, Pylypenko H, Doronin V, Usenko G, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Stevens DA, Quach H, Jagannath S, Moreau P, Levy M, Badros AZ, Anderson LD Jr, Bahlis NJ, Cavo M, Chai Y, Jeha J, Arazy M, Shah J, Shacham S, Kauffman MG, Richardson PG, Grosicki S. Mateos MV, et al. Among authors: benjamin r. J Hematol Oncol. 2021 Apr 13;14(1):59. doi: 10.1186/s13045-021-01071-9. J Hematol Oncol. 2021. PMID: 33849608 Free PMC article.
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Delimpasi S, Mateos MV, Auner HW, Gavriatopoulou M, Dimopoulos MA, Quach H, Pylypenko H, Hájek R, Leleu X, Dolai TK, Sinha DK, Venner CP, Benjamin R, Garg MK, Doronin V, Levy Y, Moreau P, Chai Y, Arazy M, Shah J, Shacham S, Kauffman MG, Richardson PG, Grosicki S. Delimpasi S, et al. Among authors: benjamin r. Am J Hematol. 2022 Mar 1;97(3):E83-E86. doi: 10.1002/ajh.26434. Epub 2021 Dec 29. Am J Hematol. 2022. PMID: 34882831 Free article. Clinical Trial. No abstract available.
Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience.
Shah V, Ko Ko T, Zuckerman M, Vidler J, Sharif S, Mehra V, Gandhi S, Kuhnl A, Yallop D, Avenoso D, Rice C, Sanderson R, Sarma A, Marsh J, de Lavallade H, Krishnamurthy P, Patten P, Benjamin R, Potter V, Ceesay MM, Mufti GJ, Norton S, Pagliuca A, Galloway J, Kulasekararaj AG. Shah V, et al. Among authors: benjamin r. Br J Haematol. 2020 Sep;190(5):e279-e282. doi: 10.1111/bjh.16935. Epub 2020 Aug 10. Br J Haematol. 2020. PMID: 32526039 Free PMC article. No abstract available.
1,038 results